Since VEGF ligand families are overexpressed in most solid cancers, standard therapeutics in human cancer therapy include inhibition of the VEGF–VEGFR2 axis by administering anti-VEGF antibodies [14]. The gene discussed is VEGFA; the disease is cancer.